Katharine Knobil
2018
In 2018, Katharine Knobil earned a total compensation of $4.1M as Chief Medical Officer and Head of Research & Development at Kaleido Biosciences.
Compensation breakdown
| Option Awards | $3,900,060 |
|---|---|
| Salary | $37,500 |
| Other | $200,389 |
| Total | $4,137,949 |
Knobil received $3.9M in option awards, accounting for 94% of the total pay in 2018.
Knobil also received $37.5K in salary and $200.4K in other compensation.
Rankings
In 2018, Katharine Knobil's compensation ranked 2,672nd out of 14,244 executives tracked by ExecPay. In other words, Knobil earned more than 81.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,672 out of 14,244 | 81st |
Division Manufacturing | 991 out of 5,765 | 83rd |
Major group Chemicals And Allied Products | 341 out of 2,128 | 84th |
Industry group Drugs | 279 out of 1,817 | 85th |
Industry Biological Products, Except Diagnostic Substances | 58 out of 339 | 83rd |
Source: SEC filing on May 8, 2020.
Knobil's colleagues
We found two more compensation records of executives who worked with Katharine Knobil at Kaleido Biosciences in 2018.